Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

By F. Wolfe, K. Michaud. Arthritis & Rheumatism, 2004

689 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/ea0cd7442388c73b315d273aac134416516c4e72

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pathology and Forensic Medicine

In Rheumatology

Citations in the corpus

British Society for Rheumatology Biologics Register (2003, result): “—the very groups that may be targeted for anti-TNF therapy. Although the risks of anti-TNF treated patients developing NHL have been calculated in comparison with national incidence rates,”
TNF-α in promotion and progression of cancer (2006, background): “An increased incidence of lymphoma has been noted in rheumatoid arthritis patients treated with anti-TNF agents compared to the general population, and placebo-treated patients, although the follow-up time for the placebo patients has been shorter than for the anti-TNF-treated patients [63].”
Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics (2006, result): “Wolfe found a threefold increased risk for lymphoma among patients in an RA registry treated with anti-TNFa as compared with SEER cancer registry data from the general public.(53) A Swedish registry study found an 11-fold increased risk for lymphoma in anti-TNFa users as compared with the general pu”
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “However, there is strong evidence that disease activity is a driving force behind the increased risk for lymphomas in patients with RA irrespective of the treatment (Baecklund et al., 1998, 2004; Wolfe & Michaud, 2004; Baecklund et al., 2006).”
The risk of lymphoma development in autoimmune diseases: a meta-analysis. (2005, result): “Studies that investigated the incidence rate of lymphomas (NHL or Hodgkin disease) without specifying the rates separately were not included.(37,48) In addition, studies that did not provide information about the expected number of NHL cases in the general population were omitted from the analysis.”
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. (2006, result): “A prospective cohort study comparing patients treated with anti-TNF therapies vs patients receiving methotrexate or no disease-modifying antirheumatic drugs (DMARDs) suggested an increased risk of hematological malignancies in anti-TNF–treated patients.(15) Because randomized trials have been too sm”